Comparative Pharmacology
Head-to-head clinical analysis: FERABRIGHT versus FERRISELTZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERABRIGHT versus FERRISELTZ.
FERABRIGHT vs FERRISELTZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy: provides elemental iron for erythropoiesis, correcting iron deficiency anemia.
Ferric iron (Fe3+) from ferric citrate reduces phosphate absorption by forming insoluble ferric phosphate complexes in the gastrointestinal tract, reducing serum phosphate levels. Iron is absorbed and incorporated into hemoglobin.
Intravenous bolus of 100 mg ferric carboxymaltose (elemental iron), administered no more than 3 times per week until iron repletion is achieved.
325-650 mg orally once daily; ferrous sulfate 325 mg (equivalent to 65 mg elemental iron).
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Not applicable for iron absorption; serum iron levels peak at 1-2 hours post-dose and decline with a half-life of approximately 6 hours, reflecting gastrointestinal absorption and distribution.
Renal elimination of unchanged drug accounts for approximately 60-70% of total clearance, with biliary/fecal excretion contributing 20-30%. The remainder undergoes hepatic metabolism.
Ferric citrate is primarily eliminated via feces as unabsorbed drug (approximately 70-80%). A small fraction is absorbed and excreted renally (less than 1% of ingested dose).
Category C
Category C
Iron Supplement
Iron Supplement